We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $100M
This Fund
S&P 500
This Quarter Est. Return
+10.1%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$101M
AUM Growth
+$3.77M
Cap. Flow
-$171K
Cap. Flow %
-0.17%
Top 10 Hldgs %
22.09%
Holding
226
New
42
Increased
62
Reduced
36
Closed
61

Top Buys

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$1.85M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$1.67M
3
TSVT
2seventy bio
TSVT
+$1.59M
4
ARQT icon
Arcutis Biotherapeutics
ARQT
+$1.37M
5
ADCT icon
ADC Therapeutics
ADCT
+$1.19M

Top Sells

Rank Stock Value
1
SHY icon
iShares 1-3 Year Treasury Bond ETF
SHY
+$12.8M
2
IWD icon
iShares Russell 1000 Value ETF
IWD
+$2.1M
3
RPV icon
Invesco S&P 500 Pure Value ETF
RPV
+$2.08M
4
WBA
Walgreens Boots Alliance
WBA
+$1.6M
5
SNY icon
Sanofi
SNY
+$1.56M

Sector Composition

Rank Sector Weight
1 Healthcare 56.8%
2 Real Estate 15.08%
3 Financials 8.32%
4 Energy 6.75%
5 Industrials 3.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COLL icon
26
Collegium Pharmaceutical
COLL
$1.17B
$1.15M 1.13%
49,500
-19,000
-28% -$383K
ADCT icon
27
ADC Therapeutics
ADCT
$172M
$1.14M 1.13%
+297,500
New +$1.19M
ONIT
28
Onity Group
ONIT
$344M
$1.09M 1.08%
35,618
– –
NVAX icon
29
Novavax
NVAX
$1.35B
$1.08M 1.07%
+105,000
New +$1.85M
BTAI icon
30
BioXcel Therapeutics
BTAI
$27.4M
$1.07M 1.06%
3,125
– –
DX
31
Dynex Capital
DX
$2.87B
$1.06M 1.05%
+83,590
New +$1.04M
AME icon
32
Ametek
AME
$54.3B
$1.05M 1.04%
7,500
– –
SLGC
33
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$1.04M 1.03%
415,000
+187,500
+82% +$523K
VRDN icon
34
Viridian Therapeutics
VRDN
$1.99B
$1.04M 1.02%
35,500
– –
STXS icon
35
Stereotaxis
STXS
$154M
$1.03M 1.02%
500,000
– –
INVA icon
36
Innoviva
INVA
$1.6B
$994K 0.98%
75,000
+7,000
+10% +$92K
SNY icon
37
Sanofi
SNY
$107B
$969K 0.96%
20,000
-35,500
-64% -$1.56M
AGNC icon
38
AGNC Investment
AGNC
$12.9B
$960K 0.95%
92,746
+54,150
+140% +$495K
RWT
39
Redwood Trust
RWT
$641M
$888K 0.88%
131,398
– –
MBLY icon
40
Mobileye
MBLY
$7.76B
$877K 0.87%
+25,000
New +$759K
PETQ
41
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
$876K 0.87%
95,000
-84,000
-47% -$784K
LNTH icon
42
Lantheus
LNTH
$7B
$866K 0.86%
+17,000
New +$1.05M
CINC
43
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$860K 0.85%
+70,000
New +$1.67M
TARO
44
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$799K 0.79%
27,500
+3,000
+12% +$89K
ACAD icon
45
Acadia Pharmaceuticals
ACAD
$4.38B
$796K 0.79%
+50,000
New +$782K
NLY icon
46
Annaly Capital Management
NLY
$16.9B
$791K 0.78%
37,500
– –
DCGO icon
47
DocGo
DCGO
$64.3M
$778K 0.77%
+110,000
New +$923K
OMCL icon
48
Omnicell
OMCL
$2.09B
$756K 0.75%
15,000
+5,000
+50% +$300K
GMED icon
49
Globus Medical
GMED
$10.5B
$743K 0.73%
10,000
+9,000
+900% +$613K
PCRX icon
50
Pacira BioSciences
PCRX
$1.01B
$734K 0.72%
+19,000
New +$924K
1
2
3 4 5

Similar funds

WCM
Weber Capital Management San Francisco, California $100M AUM
FCM
Fourier Capital Management Hong Kong $100M AUM
BIA
Baer Investment Advisory Corte Madera, California $100M AUM 23.87% 1-Year Est. Return
AGAM
Audent Global Asset Management West Hollywood, California $100M AUM 22.83% 1-Year Est. Return
E
Entelevest Coral Gables, Florida $100M AUM
HCM
Hicks Capital Management Columbus, Ohio $100M AUM 14.29% 1-Year Est. Return
AC
Arrow Capital Sydney, Australia $100M AUM 68.52% 1-Year Est. Return
OIS
OneAscent Investment Solutions Birmingham, Alabama $100M AUM 15.97% 1-Year Est. Return

AlphaCentric Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, AlphaCentric Advisors held 226 positions worth $101M, up 3.9% from $97.4M the previous quarter. Its ten largest holdings account for 22% of the portfolio.

AlphaCentric Advisors's Q4 2022 filing shows 42 new, 62 increased, 36 reduced and 61 closed positions. Its largest new stake was Novavax: 105,000 shares worth $1.08M. The largest sale was iShares 1-3 Year Treasury Bond ETF, an estimated $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 44% a quarter earlier, followed by Real Estate and Financials.

  • AlphaCentric Advisors's largest Q4 2022 buy was Novavax: 105,000 shares worth $1.08M.
  • AlphaCentric Advisors added most to 2seventy bio in Q4 2022, an estimated $1.59M increase.
  • AlphaCentric Advisors's biggest Q4 2022 reduction was Walgreens Boots Alliance, cutting an estimated $1.6M.
  • AlphaCentric Advisors fully exited iShares 1-3 Year Treasury Bond ETF in Q4 2022, selling an estimated $12.8M.
  • AlphaCentric Advisors's ten largest holdings make up 22% of its $101M portfolio in Q4 2022.
  • AlphaCentric Advisors opened 42 new positions and closed 61 in Q4 2022.
  • AlphaCentric Advisors's portfolio value rose 3.9% quarter-over-quarter to $101M.

Based on AlphaCentric Advisors's 13F filing for Q4 2022, filed 7 Feb 2023.